NASDAQ:KRON Kronos Bio (KRON) Stock Price, News & Analysis $1.00 +0.03 (+3.08%) As of 01/3/2025 05:22 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Kronos Bio Stock (NASDAQ:KRON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kronos Bio alerts:Sign Up Key Stats Today's Range$0.95▼$1.0150-Day Range$0.83▼$1.0752-Week Range$0.69▼$1.60Volume202,563 shsAverage Volume116,582 shsMarket Capitalization$60.34 millionP/E RatioN/ADividend YieldN/APrice Target$1.63Consensus RatingHold Company OverviewKronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.Read More… Kronos Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks58th Percentile Overall ScoreKRON MarketRank™: Kronos Bio scored higher than 58% of companies evaluated by MarketBeat, and ranked 489th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingKronos Bio has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKronos Bio has only been the subject of 2 research reports in the past 90 days.Read more about Kronos Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kronos Bio are expected to grow in the coming year, from ($1.33) to ($1.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kronos Bio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kronos Bio is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKronos Bio has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.28% of the float of Kronos Bio has been sold short.Short Interest Ratio / Days to CoverKronos Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kronos Bio has recently decreased by 1.06%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKronos Bio does not currently pay a dividend.Dividend GrowthKronos Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.28% of the float of Kronos Bio has been sold short.Short Interest Ratio / Days to CoverKronos Bio has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kronos Bio has recently decreased by 1.06%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Kronos Bio this week, compared to 1 article on an average week. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kronos Bio insiders have not sold or bought any company stock.Percentage Held by Insiders24.40% of the stock of Kronos Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.09% of the stock of Kronos Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kronos Bio's insider trading history. Receive KRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address KRON Stock News HeadlinesKronos Bio Ends Collaboration with Genentech and RocheDecember 27, 2024 | tipranks.comKronos Bio Inc Ordinary SharesDecember 13, 2024 | morningstar.comThe Tiny Device Behind Elon’s Next Big ThingI believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.January 6, 2025 | Brownstone Research (Ad)Struggling Bay Area biotech firm Kronos, once worth $1B, lays off almost entire staffDecember 4, 2024 | msn.comKronos Bio announces workforce reduction of 83% by year-endNovember 28, 2024 | markets.businessinsider.comKronos Bio to lay off 83% of staff as CEO steps downNovember 28, 2024 | bizjournals.comBiotech with Cambridge lab slashes 83% of staff, CEO departsNovember 28, 2024 | bizjournals.comKronos Bio CEO Norbert Bischofberger steps down, Deborah Knobelman named interimNovember 28, 2024 | markets.businessinsider.comSee More Headlines KRON Stock Analysis - Frequently Asked Questions How have KRON shares performed this year? Kronos Bio's stock was trading at $0.95 at the beginning of 2025. Since then, KRON stock has increased by 5.3% and is now trading at $1.00. View the best growth stocks for 2025 here. How were Kronos Bio's earnings last quarter? Kronos Bio, Inc. (NASDAQ:KRON) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $2.69 million for the quarter, compared to analysts' expectations of $1.75 million. Kronos Bio had a negative trailing twelve-month return on equity of 64.55% and a negative net margin of 867.66%. When did Kronos Bio IPO? Kronos Bio (KRON) raised $175 million in an initial public offering on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of Kronos Bio? Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Kronos Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kronos Bio investors own include Bank of America (BAC), AT&T (T), Taseko Mines (TGB), Energy Transfer (ET), ARMOUR Residential REIT (ARR), Prospect Capital (PSEC) and New Gold (NGD). Company Calendar Last Earnings8/08/2024Today1/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRON CUSIPN/A CIK1741830 Webkronosbio.com Phone650-781-5200FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$1.63 High Stock Price Target$2.25 Low Stock Price Target$1.00 Potential Upside/Downside+62.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,670,000.00 Net Margins-867.66% Pretax Margin-867.66% Return on Equity-64.55% Return on Assets-48.18% Debt Debt-to-Equity RatioN/A Current Ratio8.32 Quick Ratio8.32 Sales & Book Value Annual Sales$9.86 million Price / Sales6.12 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book0.37Miscellaneous Outstanding Shares60,341,000Free Float45,618,000Market Cap$60.34 million OptionableOptionable Beta1.83 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:KRON) was last updated on 1/6/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredDonald Trump is about to free crypto from its chains …With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.